Skip to main content
SpringerLink
Log in

Translation of pharmacokinetics to clinical medicine

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The translation of pharmacokinetics to clinical medicine involves answering the following question: “When the pharmacodynamic or chemotherapeutic activity of a drug is known, how must its dosage regimen be adapted to its pharmacokinetic characteristics so that the desired therapeutic effect may be achieved and maintained?” This presentation discusses examples of pharmacokinetic analyses which influence the practice or principles of practical therapeutics. Physicians have intuitively appreciated the basic importance of pharmacodynamics because they are primarily interested in the action of a drug on the patient. However, in pharmacokinetics we consider the fact that there is not only a unidirectional action but also a mutual interaction between drug and organism. The action of the organism on the drug may be summarized in terms of the pharmacokinetic parameters: absorption, distribution, metabolism, and excretion. These parameters are examined with respect to drug accumulation, relation of pharmacokinetic data to therapeutic effects, saturation phenomena, the effect of kidney disease, the variation of pharmacokinetic parameters in individual patients due to age, pH of body fluids, and the states of wakefulness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. E. J. Ariens (ed.).Molecular Pharmacology, Vol. 1, Academic Press, New York, 1964.

    Google Scholar 

  2. R. Dominguez. Kinetics of elimination absorption and volume of distribution in the organism. In O. Glasser (ed.).Medical Physics, Vol. 2, Year Book Publishers, Chicago, 1950, pp. 476–489.

    Google Scholar 

  3. E. Krüger-Thiemer. Dosage schedule and pharmacokinetics in chemotherapy.J. Am. Pharm. Ass. Sci. Ed. 49: 311–313 (1960).

    Article  Google Scholar 

  4. E. Krüger-Thiemer. Sulfanilamide und verwandte Chemotherapeutica. InHandbuch Haut- u. Geschlechtskrankh., Erg. Werk Bd. V/1:Therapie der Hautkrankheiten (Hrsg. Prof. J. Kimmig), Springer-Verlag, Berlin, Göttingen, Heidelberg, 1962. pp. 962–1122.

    Google Scholar 

  5. E. Nelson. Kinetics of drug absorption, distribution, metabolism and excretion.J. Pharm. Sci. 50: 181–192 (1961).

    Article  CAS  PubMed  Google Scholar 

  6. E. Freerksen, L. Dettli, E. Krüger-Thiemer, and E. Nelson. Colloquium of pharmaco-kinetics and drug dosage, Borstel, 1962.Antibiotica et Chemotherapia, Vol. 12, Karger. Basel, 1964.

    Google Scholar 

  7. L. Dettli and P. Spring.Proc. 3rd Internat. Congr. Pharmacol., Vol. 7, Pergamon Press, Oxford, 1968.

    Google Scholar 

  8. F. H. Dost.Der Blutspiegel, Thieme, Leipzig, 1953.

    Google Scholar 

  9. F. H. Dost.Grundlagen der Pharmakokinetik, Thieme, Stuttgart, 1968.

    Google Scholar 

  10. J. G. Wagner.Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, Ill., 1971.

    Google Scholar 

  11. World Health Organization Scientific Group. Principles for pre-clinical testing of drug safety.World Health Org. Tech. Rep. Ser. 341: 7 (1966).

    Google Scholar 

  12. L. Dettli. In H. P. Kuemmerle, E. R. Garrett, and K. H. Spitzy (eds.),Klinische Pharmakologie und Pharmakotherapie, Urban and Schwarzenberg, Munich, 1971.

    Google Scholar 

  13. T. Teorell. Kinetics of distribution of substances administered to the body. I. The extra-vascular modes of administration.Arch. Int. Pharmacodyn. 57: 205–225 (1937).

    CAS  Google Scholar 

  14. T. Teorell. Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration.Arch. Int. Pharmacodyn. 57: 226–240 (1937).

    CAS  Google Scholar 

  15. L. Dettli. Multiple dose elimination kinetics and drug accumulation in patients with normal and with impaired kidney function. In G. Raspé (ed.).Advances in the Biosciences, Vol. 5, Pergamon Press and Vieweg, Oxford, New York, and Braunschweig, 1970, pp. 39–54.

    Google Scholar 

  16. G. Levy. Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects.J. Pharm. Sci. 53: 342–343 (1964).

    Article  CAS  PubMed  Google Scholar 

  17. G. Levy. Kinetics of pharmacologic effects.Clin. Pharmacol. Therap. 7: 362–372 (1966).

    CAS  Google Scholar 

  18. G. Levy and E. Nelson. Theoretical relationship between dose, elimination rate and duration of pharmacologic effect of drugs.J. Pharm. Sci. 54: 812 (1965).

    Article  CAS  PubMed  Google Scholar 

  19. E. Krüger-Thiemer. Die experimentelle Bewertung neuer Sulfanilamide als Vorbereitung ihrer klinischen.Prüfung. Klin. Wschr. 40: 153–158 (1962).

    Article  Google Scholar 

  20. L. Dettli. In F. Koller (ed.),Pathogenesis and Treatment of Thromboembolic Diseases, Schattauer, Stuttgart, 1966.

    Google Scholar 

  21. W. Scholtan. Die Bindung der Langzeit-Sulfonamide an die Eiweisskorper des Serums.Arzneim.-Forsch. 11(8): 707–720 (1961).

    CAS  Google Scholar 

  22. W. Scholtan. Binding of long-acting sulfonamides on human serum proteins.Makromol. Chem. 54: 24–59 (1962).

    Article  CAS  Google Scholar 

  23. P. Spring. Die Bindung einiger Sulfanilamide an die Bluteiweisskörper des Menschen.Arzneim.-Forsch. 16(3): 346–354 (1966).

    CAS  Google Scholar 

  24. L. Dettli and P. Spring.Regensburg. Jb. Aerztl. Fortbild. 14: 17 (1966).

    Google Scholar 

  25. E. Krüger-Thiemer, P. Bünger, L. Dettli, P. Spring, and E. Wempe. Dosage regimen calculation of chemotherapeutic agents. III. Sulfasymazine.Chemotherapia 10: 325–338 (1965/1966).

    Article  Google Scholar 

  26. E. Krüger-Thiemer, H. Berlin, P. Brante, P. Bünger, L. Dettli, P. Spring, and E. Wempe. Dosage regimen calculation of chemotherapeutic agents.Chemotherapy 14: 273–302 (1969).

    Article  PubMed  Google Scholar 

  27. P. Bünger, W. Diller, J. Führ, and E. Krüger-Thiemer. Vergleichende Untersuchungen an Sulfanilamiden. I.Arzneim.-Forsch. (Drug Res.) 11: 247–255 (1961).

    Google Scholar 

  28. P. Bünger. Die klinische Bewertung neuer Sulfanilamide.Chemotherapia 6: 237–242 (1963).

    Article  PubMed  Google Scholar 

  29. W. D. Heizer, T. W. Smith, and S. E. Goldfinger. Absorption of digoxin in patients with malabsorption syndromes.New Engl. J. Med. 285: 257–259 (1971).

    Article  CAS  PubMed  Google Scholar 

  30. L. Dettli and P. Spring. Factors influencing drug elimination in man.Il. Farmaco (Sci. Ed.) 23: 795–812 (1968).

    CAS  Google Scholar 

  31. B. B. Brodie, J. J. Burns, and M. Weiner. Metabolism of drugs in subjects with Laennec's cirrhosis.Med. Exptl. 1: 290–292 (1959).

    CAS  Google Scholar 

  32. P. D. A. Evans.Med. Hyg. 20: 905 (1962).

    Google Scholar 

  33. W. Kalow.Pharmacogenetics, Saunders, Philadelphia 1972.

    Google Scholar 

  34. B. Krauer, P. Spring, and L. Dettli. Pharmacokinetics of two sulfonamides in the infant.Pharmacol. Clin. 1(2): 47–53 (1968).

    Article  CAS  Google Scholar 

  35. B. Krauer. Unpublished observations.

  36. H. Otaya. Personal communication.

  37. H. Rind and E. Gladtke. Pharmakokinetische Untersuchungen zur Sulfonamidtherapie bei Trimenonkindern.Monatschr. Kinderheilk. 112(4): 239–240 (1964).

    CAS  Google Scholar 

  38. M. D. Milne, B. H. Scribner, and M. A. Crawford. Non-ionic diffusion and the excretion of weak acids and bases.Am. J. Med. 24: 709–729 (1958).

    Article  CAS  PubMed  Google Scholar 

  39. H. B. Kostenbauder, J. B. Portnoff, and J. V. Swintosky. Control of urine pH and its effect on sulfaethidole excretion in humans.J. Pharm. Sci. 51: 1084–1089 (1962).

    Article  CAS  PubMed  Google Scholar 

  40. L. Dettli and P. Spring.Proc. 3rd Internat. Congr. Chemotherap. Vol. 1. Thieme, Stuttgart, 1964.

    Google Scholar 

  41. M. Rowland. A. H. Beckett, and P. Turner. Influence of urinarypH on excretion of amphetamine.Lancet 1: 303 (1965).

    PubMed  Google Scholar 

  42. L. Dettli, P. Spring, and I. Raeber.Internat. J. Clin. Pharmacol. Therap. Toxicol. 1: 130 (1967).

    Google Scholar 

  43. R. I. Birchfield, H. O. Sieker, and A. Heyman. Alterations in respiratory function during natural sleep.J. Lab. Clin. Med. 54: 216–222 (1959).

    CAS  PubMed  Google Scholar 

  44. L. Dettli and P. Spring. Diurnal variations in the elimination rate of a sulfonamide in man.Helv. Med. Acta 33(4): 291–306 (1967).

    CAS  PubMed  Google Scholar 

  45. P. Spring, L. Dettli, and I. Raeber.Proc. 5th Internat. Congr. Chemotherap., Vol. 4, Thieme, Stuttgart, 1967.

    Google Scholar 

  46. B. Krauer and L. Dettli. Diurnal variations in the elimination rate of sulfisomidine in children during the first year of life.Chemotherapy 14: 1–6 (1969).

    Article  CAS  PubMed  Google Scholar 

  47. B. Krauer, Intraindividuelle Variabilität der Arzneimittel-Elimination.Z. Kinderheilk. 108: 231–237 (1970).

    Article  CAS  PubMed  Google Scholar 

  48. N. Kleitman.Sleep and Wakefulness, University of Chicago Press, Chicago, 1963.

    Google Scholar 

  49. G. Levy. Dose-dependent effects in pharmacokinetics. In D. H. Tedeschi and R. E. Tedeschi (eds.),Importance of Fundamental Principles in Drug Evaluation, Raven Press, New York, 1968, pp. 141–172.

    Google Scholar 

  50. G. Levy, I. Tsuchiya, and L. P. Amsel. Limited capacity for salicyl phenolic glucuronide formation and its effects on the kinetics of salicylate elimination in man.Clin. Pharmacol. Therap. 13: 258–268 (1972).

    CAS  Google Scholar 

  51. G. Levy. Drug biotransformation interactions in man:Nonnarcotic analgesics.Ann. N. Y. Acad. Sci. 179: 32–42 (1971).

    Article  CAS  PubMed  Google Scholar 

  52. W. A. Silverman, D. H. Andersen, W. A. Blanc, and D. M. Crozier. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens.Pediatrics 18: 614–625 (1956).

    PubMed  Google Scholar 

  53. A. H. Anton. The relation between the binding of sulfonamides to albumin and their antibacterial efficacy.J. Pharmacol. Exptl. Therap. 129: 282–290 (1960).

    CAS  Google Scholar 

  54. M. M. Reidenberg.Renal Function and Drug Action, Saunders, Philadelphia, 1971.

    Google Scholar 

  55. L. Dettli. Der Konzentrationsbegriff in der Chemotherapie mit Sulfanilamiden.Arzneim.-Forsch. 11(9): 861–866 (1961).

    CAS  Google Scholar 

  56. E. Krüger-Thiemer, E. Wempe, and M. Töpfer. Die antibakterielle Wirkung des nicht eiweissgebundenen Anteils der Sulfanilamide im menschlichen Plasmawasser.Arzneim.-Forsch. (Drug. Res.) 15: 1309–1317 (1965).

    Google Scholar 

  57. L. Dettli. Drug dosage in patients with kidney disease:Theory and practice. Abstracts of the APhA Academy of Pharmaceutical Sciences Houston Meeting, April, 1972.

  58. G. Levy.Proc. 4th Internat. Congr. Pharmacol., Vol. 4, Schwabe, Basel. 1969.

    Google Scholar 

  59. J. R. Gillette. Problems associated with the extrapolation of data fromin vitro experiments to experiments in intact animals. In:D. H. Tedeschi and R. E. Tedeschi (eds.).Importance of Fundamental Principles in Drug Evaluation, Raven Press, New York, 1968, pp. 69–84.

    Google Scholar 

  60. M. Kristensen and L. K. Christensen.Acta Diabetol. 6: 116 (1968).

    Google Scholar 

  61. G. T. Okita and G. H. Acheson.Proc. 5th Internat. Congr. Pharmacol., Vol. 3, Karger, Basel, 1972.

    Google Scholar 

  62. C. M. Kunin and M. Finland. Restrictions imposed on antibiotic therapy by renal failure.A.M.A. Arch. Int. Med. 104: 204–224 (1959).

    Article  Google Scholar 

  63. C. M. Kunin. A guide to use of antibiotics in patients with renal disease.Ann. Int. Med. 67: 151–158 (1967).

    Article  CAS  PubMed  Google Scholar 

  64. C. M. Kunin. More on antimicrobials in renal failure.Ann. Int. Med. 69: 397–398 (1968).

    Article  CAS  PubMed  Google Scholar 

  65. R. W. Jelliffe. A mathematical analysis of digitalis kinetics in patients with normal and reduced renal function.Math. Biosci. 1: 305–325 (1967).

    Article  CAS  Google Scholar 

  66. L. Dettli. Drug dosage in patients with impaired kidney function.Postgrad. Med. J. 46: 32–35 (1970).

    Article  Google Scholar 

  67. L. Dettli, P. Spring, and S. Ryter. Multiple dose kinetics and drug dosage in patients with kidney disease.Acta Pharmacol. Toxicol. Scand. 29:Suppl. 3, 211–224 (1971).

    CAS  Google Scholar 

  68. L. Dettli. P. Spring, and S. Ryter. Arzneimitteldosierung bei Niereninsuffizienz. In R. Kluthe (ed.),Freiburger Tagung über Fortschritte der Nephrologie, Thieme, Stuttgart, 1971. pp. 61–70.

    Google Scholar 

  69. L. Dettli and P. Spring.Proc. 5th Internat. Congr. Pharmacol., Vol. 3, Karger, Basel, 1972.

    Google Scholar 

  70. P. Spring, M. Buergi, L. Dettli, and H. Reber.Praxis 15: 479–481 (1973).

    Google Scholar 

  71. L. Dettli and P. Spring.Proc. 4m Internat. Congr. Pharmacol., Vol. 1, Basel and Stuttgart, 1970.

Download references

Author information

Authors and Affiliations

  1. Clinic 2, Department of Internal Medicine, University of Basel, 4000, Burgerspital, Basel, Switzerland

    Lucius Dettli

Authors
  1. Lucius Dettli
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Aided by Schweizerischer Nationalfonds zur Förderung der wissenschaftlichen Forschung.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dettli, L. Translation of pharmacokinetics to clinical medicine. Journal of Pharmacokinetics and Biopharmaceutics 1, 403–418 (1973). https://doi.org/10.1007/BF01059665

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01059665

Key words

Search

Navigation